alexa SGLT2 Inhibitor and DPP4 Inhibitor Co-Administration In Type 2 Diabetes -Are We Near The Promised Land? | Abstract
e-ISSN: 2322-0139 p-ISSN: 2322-0120

Research & Reviews: Journal of Pharmacology and Toxicological Studies
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Diabetes is progressive disease needing multiple drugs for achieving and maintaining good glycemic control. The drugs with different mechanisms of action are administered either alone or as fixed dose combinations. Usually the combined effect of each is less than the added effect except with Metformin DPP-4 inhibitor combination because they seldom complement/synergise each other’s action. More of such effective drug combinations that provide glycemic control are needed. SGLT 2 inhibitor, when combined with DPP4 inhibitor has the potential to be that ideal combination. Both of these drugs address different pathophysiological mechanisms for hyperglycemia and when combined provide reductions in HbA1c level with no inherent risk of hypoglycaemia. Genitourinary infection, a major hindrance with SGLT 2 inhibitor use are potentially reduced when it is combined with DPP4 inhibitor, which also can counteract the increase in glucagon level produced by the former. Cost, differing applicability in patients with renal dysfunction and limited clinical experience restricts the universal application of this combination as first line agents.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Ayesha Vaseem, Bipin K Sethi, Jayant V Kelwade, Mazher Ali


Diabetes, Metformin, SGLT 2 inhibitor, DPP4inhibitor, Pathophysiology, Pharmacoepidemiology studies, Comparative pharmacology

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version